Results 51 to 60 of about 2,230 (120)

Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon‐Like Peptide 1 Agonist: A Case Report

Respirology Case Reports, Volume 14, Issue 3, March 2026.
Cystic fibrosis (CF) modulator therapies can lead to rapid and excessive weight gain. Obesity in CF can lead to undesirable metabolic complications including type 2 diabetes. Therefore, glucagon‐like peptide 1 (GLP‐1) agonists which can facilitate weight loss and improve metabolic profiles are increasingly prescribed to people with CF.
Shanal Kumar, Robyn Cobb, Angela Matson, Joseph Lee, Daniel Henderson   +4 more
wiley   +1 more source

Obstetric and Neonatal Outcomes in Pregnancies From a Dedicated Cystic Fibrosis‐Maternal Health Service: A Retrospective Study

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 4, Page 690-697, March 2026.
ABSTRACT Objective A comprehensive review of maternal, obstetric and neonatal outcomes in pregnancies in females with cystic fibrosis (fwCF) following the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy in a novel, dedicated CF‐Maternal Health service.
Rebecca Scott, Amy Downes, Ladina Weitnauer, Rebecca Dobra, Natasha Singh, Rachel Robinson, Emily Diable, Saraha Collins, Elaine Bowman, Thomas Tobin, Andrew Jones, Nicholas Simmonds, Imogen Felton   +12 more
wiley   +1 more source

Divergent neurobehavioral effects of CFTR modulators elexacaftor and ivacaftor in mice

Acta Psychologica
Recent advances in cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination therapies have markedly improved survival and quality of life for people with cystic fibrosis (CF).
Qian Ge, Amy Fagan, Hui Lu, Jianyang Du, Leah R. Reznikov   +4 more
doaj   +1 more source

Management of Cystic Fibrosis‐Related Diabetes in Denmark—A Population‐Based, Cross‐Sectional Study

Pediatric Pulmonology, Volume 61, Issue 2, February 2026.
ABSTRACT Background Cystic fibrosis‐related diabetes (CFRD) is the most common comorbidity in cystic fibrosis (CF). After the introduction of modulator therapy, extended life expectancy and altered nutritional status may have changed the landscape of CFRD. This study aimed to evaluate the current CFRD management in Denmark.
Ingrid Grimsgaard, Esben Herborg Henriksen, Bibi Uhre Nielsen, Daniel Faurholt‐Jepsen, Majbritt Jeppesen, Thomas Almdal, Esben Søndergaard   +6 more
wiley   +1 more source

Effects of cAMP and CFTR modulation on apical fluid pH in human airway Calu‐3 cells

Physiological Reports, Volume 14, Issue 3, February 2026.
Abstract The airway epithelium serves as the first line of defense against inhaled insults present in the external environment by acting as a physical barrier and through host defense mechanisms. Proper maintenance of these host defense mechanisms relies on the regulation of airway surface liquid (ASL) composition and properties, a process that is ...
Jenny P. Nguyen, Nadia Milad, Jeremy A. Hirota   +2 more
wiley   +1 more source

Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor

Molecules
The monogenic rare disease Cystic Fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance (CFTR) protein, an anion channel expressed at the apical plasma membrane of epithelial cells.
Filipa C. Ferreira, Camilla D. Buarque, Miquéias Lopes-Pacheco   +2 more
doaj   +1 more source

Mejoría de la inflamación intestinal tras tratamiento con moduladores de la proteína CFTR en pacientes con fibrosis quística

Anales de Pediatría
Resumen: Introducción: Los tratamientos con moduladores de la proteína CFTR han mejorado la salud respiratoria y digestiva de los pacientes con fibrosis quística.
Ruth García Romero, Concepción López Cárdenes, Elena Crehuá Gaudiza, Marina Álvarez Beltrán, Mercedes Murray Hurtado, Carlos Tutau Gómez, Inés Loverdos Eseverri, Encarni Torcuato Rubio, Camila García Volpe, Enrique Salcedo Lobato, María Medina Martínez, Carmen Martin Fernández, Ana Moreno Álvarez, Ana Reyes Domínguez, David González Jiménez   +14 more
doaj   +1 more source

Co‐Design of a Novel Telehealth Exercise Model of Care for Adults With Cystic Fibrosis

Pediatric Pulmonology, Volume 61, Issue 3, March 2026.
Megan Poulsen, Arwel W. Jones, Brenda Button, Anne E. Holland   +3 more
wiley   +1 more source

Improvement of intestinal inflammation after treatment with CFTR modulators in cystic fibrosis patients

Anales de Pediatría (English Edition)
Introduction: Treatments with CFTR protein modulators have improved respiratory and digestive health in patients with cystic fibrosis. Objective: To assess changes in intestinal inflammation through the analysis of fecal calprotectin in patients with ...
Ruth García Romero, Concepción López Cárdenes, Elena Crehuá Gaudiza, Marina Álvarez Beltrán, Mercedes Murray Hurtado, Carlos Tutau Gómez, Inés Loverdos Eseverri, Encarni Torcuato Rubio, Camila García Volpe, Enrique Salcedo Lobato, María Medina Martínez, Carmen Martin Fernández, Ana Moreno Álvarez, Ana Reyes Domínguez, David González Jiménez, Saioa Vicente Santamaría, Ana Tabares González, Jose Ramon Gutierrez Martinez, Sara Sierra San Nicolás, Pilar Ortiz Pérez, Luis Peña Quintana   +20 more
doaj   +1 more source

Editorial: Real-world experience with CFTR modulator therapy

Frontiers in Pharmacology, 2023
Burkhard Tümmler, Burkhard Tümmler, Pierre-Régis Burgel, Pierre-Régis Burgel   +3 more
doaj   +1 more source